ICML 2017 | Exciting times for Waldenström’s macroglobulinemia: new treatments and tools
Steven Treon, MD, PhD, from Dana-Farber Cancer Institute, USA, provides us with a run down of the significant progress made in the understanding of Waldenström’s macroglobulinemia disease pathogenesis and the development of treatments targeted to the condition. He discusses the discovery of mutated genes that can be used as diagnostic tools and the signaling pathways associated with driving this cancer. This understanding allowed us to see how ibrutinib could be used to treat patients with Waldenström’s macroglobulinemia in an investigator-led trial, which he summarises. Dr Treon also talks about the CXCR4 mutation, which is important for mediating drug resistance, including to ibrutinib. Ulocuplumab is an agent that targets CXCR4 and could be important for patients who develop ibrutinib resistance.
This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of the content.
